VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions and leveraging our collective expertise to improve patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver quality medicines to patients when and where they need them.

OUR MISSION
At Viatris, we see healthcare not as it is, but as it should be. We act courageously and are uniquely positioned to be a source of stability in a world of evolving healthcare needs.

Viatris empowers people worldwide to live healthier at every stage of life.

We do so via:

ACCESS
providing high quality, trusted medicines to patients regardless of geography or circumstance

LEADERSHIP
advancing sustainable operations and innovative solutions to improve patient health

PARTNERSHIP
leveraging our collective expertise to connect people to products and services

OUR LEADERS
Our seasoned executive management team and board of directors bring decades of expertise, knowledge and strategic vision to Viatris. Together with our dedicated and talented global workforce, our leadership is committed to increasing access to medicine for patients around the world while unlocking value for shareholders.

OUR PRODUCTS
Our global portfolio includes medicines across a broad range of major therapeutic areas, spanning both noncommunicable and infectious diseases.

Brands
Best-in-class, iconic brand-name products and global key brands

Generics
A diverse range of generic medicines, including branded and complex generics

Biosimilars
One of the industry’s largest and most diverse global biosimilars franchises focused on the areas of oncology, immunology, endocrinology, ophthalmology and dermatology

Over-the-counter (OTC)
Variety of OTCs, including dietary supplements, homeopathics and cosmetics

Active Pharmaceutical Ingredients (API)
One of the world’s largest producers of APIs

FAST FACTS

NASDAQ Ticker: VTRS

Offices:
Headquartered in the U.S. with global centers in Pittsburgh, Hyderabad and Shanghai

Global Workforce: ~45,000
Including expertise across scientific, manufacturing, regulatory, commercial and medical

Manufacturing Facilities: ~50
Across oral solid doses, injectables, complex dosage forms and API

Annual Production Capacity:
80+ billion doses

Molecules: 1,400+
• Portfolio that treats nine out of 10 WHO leading causes of death
• 200+ medicines on WHO Essential Medicines List

Commercial Reach:
165+ countries and territories

Customers: 60,000+
Including retail and pharmacy establishments, wholesalers, governments, institutions and physicians
Creating better value for all stakeholders while addressing unmet needs.

Committed to Corporate Social Responsibility

PATIENT HEALTH
An industry leader with products that are capable of addressing nine of the top 10 causes of death globally and serving more than 165 countries and territories including close to 90% of low and lower-middle-income countries.²

EMPLOYEE HEALTH
Committed to providing a safe, positive, and productive work environment that fosters inclusion, integrity, dignity and mutual respect.

COMMUNITY HEALTH
Support efforts to enhance the quality of life and meet needs in and around the communities where Viatris operates.

ENVIRONMENTAL HEALTH
Responsible environmental stewardship and promoting safe and sustainable operations is a priority.

GLOBAL PUBLIC HEALTH
Leverage our global footprint to advocate for responsible public policy, prioritizing patient health, access to medicine, including in low-income countries, and the acceptance of generics and biosimilars.

² According to the World Health Organization. For additional information, please visit: https://extranet.who.int/prequal/